IndSwift

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED
30TH SEPTEMBER, 2006

(RS. IN LACS)

PARTICULARS	Unaudited quarter 30.09.2006	Unaudited quarter 30.09.2005	Unaudited Half Year 30.09.2006	Unaudited Half Year 30.09.2005	Audited Year End 31.03.2006
SALES	9100.61	7675.05	17443.07	14728.21	27437.56
Others Income	12.11	16.82	23.71	27.56	182.73
TOTAL INCOME	9112.72	7691.87	17466.78	14755.77	27620.29
Total Expenditure	7912.94	6789.33	15237.42	13065.43	24186.29
Decrease in Stock in trade	-163.73	-556.43	-394.70	-275.30	-516.59
Consumption of raw material	6902.06	6278.56	12464.20	11342.52	20760.28
Cost of Sales	6738.33	5722.13	12858.90	11067.22	20243.69
Staff Cost	302.30	228.56	592.17	454.73	1107.36
Other expenses	872.31	838.64	1786.35	1543.48	2835.24
Interest	383.33	219.89	713.43	418.51	1093.84
Depreciation	69.20	33.99	137.35	66.70	146.48
PROFIT BEFORE TAX	747.25	648.66	1378.58	1205.13	2193.68
Provision for Tax(Incl. FBT.)	91.68	48.65	170.36	90.38	214.78
Provision for Deferred Tax	66.15	28.39	118.30	30.89	252.29
Net Profit	589.42	571.62	1089.92	1083.86	1726.61
Share Capital	743.57	743.57	743.57	743.57	743.57
Reserves excluding					11934
Revaluation Reserves EPS(Basic & Diluted)	1.59	1.54	2.93	2.92	4.64
AGGREGATE OF NON-PROMOTERS SHAREHOLDING
NUMBER OF SHARES	24056475	24056475	24056475	24056475	24056475
% OF SHARE HOLDING	64.70%	64.70%	64.70%	64.70%	64.70%

NOTES:
1. During the quarter under review, the turnover of the company grew by 18.57% and profit before Tax grew by 15.17% compared to same period during previous year. 2. The coming up of the two new facilities in the Tax free zones at Samba(J&K) and Baddi(H.P) has resulted in the overall improvement in the operational costs which is expected to improve further in the coming quarters. 3. The Company has filed over 100 product dossiers in countries of Africa,South East Asia,South America & CIS.Going forward,Exports will contribute significantly towards the topline and bottomline growth of the company. 4. The Company's new 100% Export Oriented Facility at Derabassi,Punjab,confirms to stringent TGA-Australia,MHRA-UK, MCC-South Africa & ANVISA-Brazil requirements and the unit is ready for an audit and accredition by these bodies including WHO-Geneva. 5. During the Quarter, the company has introduced 18 new products in the market. 6.The above results were reviewed by the audit committee and taken on record by Board of Directors of the company by their respective meetings held on 28th October 2006. 7 The company had recieved 04 investors complaints during the quarter under review and all of these were redressed and disposed off .Their were no pending complaints either at the beginning or end of the quarter. 8.The Company is exclusively in the Pharmaceutical business segment. 9. Previous Year Figures have been re-grouped and/or re-arranged wherever considered necessary.

For and on Behalf of the Board of Directors
Sd/-


Dated: 28.10.2006		Dr.Gopal Munjal

Place: Chandigarh		Chairman